Doripenem

Structural formula
General
Non-proprietary name	Doripenem
other names	Doripenemum ( Latin )
Molecular formula	C 15 H 24 N 4 O 6 S 2
External identifiers / databases
PubChem	73303
ChemSpider	66040
DrugBank	DB06211
Wikidata	Q411552
Drug information
ATC code	J01 DH04
Drug class	β-lactam antibiotics , carbapenems
Mechanism of action	Inhibition of cell wall synthesis
properties
Molar mass	420.50 g · mol -1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Doripenem is an antibiotic active substance from the group of carbapenems . Doripenem was approved in Europe from July 2008 to July 2014 ( trade name Doribax ) for the treatment of nosocomial pneumonia, including ventilation pneumonia , complicated infections of the abdomen ( intrabdominal infections) and complicated urinary tract infections . The market withdrawal in 2014 took place after the license rights were returned to the Japanese pharmaceutical company Shionogi .

pharmacology

The mode of action corresponds to that of the carbapenems . By introducing a β-methyl group in position 4, doripenem, in contrast to imipenem, is stable to dehydropeptidase I. It is administered intravenously as a continuous infusion.

Spectrum of activity

Doripenem shows a stronger activity against gram-positive cocci than meropenem and a stronger activity against gram-negative rods than imipenem. Study data show a particularly good effect against Pseudomonas aeruginosa and enterobacteria, including strains that are resistant to other antibiotics.

Side effects

Doripenem was well tolerated in all clinical studies. With regard to safety, a comparable profile to meropenem has been demonstrated for doripenem in clinical studies. The most common side effects that can occur are headache, diarrhea and nausea.

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ ^a ^b Public Assessment Report (EPAR) of the European Medicines Agency (EMA) on: Doribax .
↑ doripenem - withdrawal in Germany , Pharmaceutical newspaper, online edition 12/2014.
↑ M. Mori; M. Hikida; T. Nishihara; T. Nasu; S. Mitsuhashi: Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I , Journal of Antimicrobial Chemotherapy 37, 1034-1036, 1996.
↑ Shazad Mushtaq; Yigong Ge; David M. Livermore: Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential , Antimicrobial Agents and Chemotherapy 48, 3086-3092, 2004, doi : 10.1128 / AAC.48.8.3086-3092.2004 .

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[EPAR-2] Public Assessment Report (EPAR) of the European Medicines Agency (EMA) on: Doribax .

[3] doripenem - withdrawal in Germany , Pharmaceutical newspaper, online edition 12/2014.

[4] M. Mori; M. Hikida; T. Nishihara; T. Nasu; S. Mitsuhashi: Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I , Journal of Antimicrobial Chemotherapy 37, 1034-1036, 1996.

[5] Shazad Mushtaq; Yigong Ge; David M. Livermore: Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential , Antimicrobial Agents and Chemotherapy 48, 3086-3092, 2004, doi : 10.1128 / AAC.48.8.3086-3092.2004 .